Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276

R. J. Babaian, J. L. Murray, L. M. Lamki, T. P. Haynie, E. M. Hersh, M. G. Rosenblum, H. J. Glenn, M. W. Unger, D. J. Carlo, A. C. von Eschenbach

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

A total of 25 patients with histologically proved adenocarcinoma of the prostate, whose disease was staged clinically as D2 by appropriate radiographic and nuclear medicine studies, received increasing doses of PAY 276, an antiprostatic acid phosphatase monoclonal antibody for radioimmunological imaging. The patients were divided into 5 groups of 5. Groups 1 through 5 received an infusion of 5, 10, 20, 40 or 80 mg. monoclonal antibody, respectively, 1 mg. of which was labeled to 5 mCi. of 111indium, while stable monoclonal antibody was added to achieve the desired antibody concentration. No patient had an allergic reaction, and no significant change in serial hemoglobin levels, platelet count, chemistry profile or results of urinalyses was noted. The monoclonal antibody scan visualized at least 1 lesion in 19 of 25 patients (76 per cent): 4 in groups 1 and 2, and all 15 in groups 3 to 5. With results of conventional radiography and bone scintigraphy considered definitive for metastases, monoclonal antibody scans detected 7 of 32 metastases (21.8 per cent) in group 3 (20 mg.), 31 of 58 (53.4 per cent) in group 4 (40 mg.) and 101 of 134 (75.4 per cent) in group 5 (80 mg). In group 5 the incidence of false positive and false negative scans was 2.3 per cent (3 of 132) and 24.6 per cent (33 of 134), respectively. The detection of metastatic lesions increased as the concentration of unlabeled monoclonal antibody increased. Radioimmunological imaging of prostatic cancer with antiprostatic acid phosphatase monoclonal antibody seems to be feasible.

Original languageEnglish (US)
Pages (from-to)439-443
Number of pages5
JournalJournal of Urology
Volume137
Issue number3
DOIs
StatePublished - Jan 1 1987

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Radioimmunological imaging of metastatic prostatic cancer with <sup>111</sup>indium-labeled monoclonal antibody PAY 276'. Together they form a unique fingerprint.

  • Cite this

    Babaian, R. J., Murray, J. L., Lamki, L. M., Haynie, T. P., Hersh, E. M., Rosenblum, M. G., Glenn, H. J., Unger, M. W., Carlo, D. J., & von Eschenbach, A. C. (1987). Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276. Journal of Urology, 137(3), 439-443. https://doi.org/10.1016/S0022-5347(17)44060-2